Celltrion's Vegzelma, a biosimilar of Roche's anticancer drug Avastin, has captured a 12 percent market share in Japan, despite being the latest among four bevacizumab biosimilar products in the country. Since its launch in January last year, Vegzelma has experienced rapid growth, attributed to collaboration with Japanese distribution partners and the inclusion of anticancer drugs in the Japanese medical service reimbursement system, which makes it more profitable for hospitals to prescribe biosimilars. Additionally, Celltrion's other biosimilar products, Herzuma and Remsima, have also achieved significant market shares in Japan's trastuzumab and infliximab markets, respectively. The success of these products has contributed to the marketing efforts of Vegzelma in the country. Celltrion aims to further enhance its sales capacity to facilitate the entry of its other biosimilar products, such as Yuflyma, into the Japanese market.